Bangalore, September 20, 2019- Strides Pharma Science Limited (Strides or Company) today
announced that the Board of Directors of the Company have approved an additional
investment up to a maximum of ~US$ 40 million over a period of 24 months for a controlling
stake in Stelis Biopharma Private Limited (Stelis).
The proposed new investments will be a primary infusion into Stelis which will enable Stelis
to achieve its objective of becoming a compelling global player in the biopharmaceutical
space and also accelerate Strides’ re-entry into sterile injectables business post the
completion of the Company’s non-compete period in December 2019.
Read the full article here.